21:16:05 EDT Fri 11 Sep 2026
Enter Symbol
or Name
USA
CA



Sernova Biotherapeutics Inc
Symbol SVA
Shares Issued 377,642,509
Close 2026-09-11 C$ 0.135
Market Cap C$ 50,981,739
Recent Sedar+ Documents

Sernova shareholder Sangha to vote "yes" in takeover

2026-09-11 17:59 ET - News Release

Dr. Steven Sangha, Seraxis shareholder, report

STEVEN SANGHA ANNOUNCES VOTING AND SUPPORT AGREEMENT FOR SERNOVA BIOTHERAPEUTICS INC.'S PROPOSED BUSINESS COMBINATION WITH SERAXIS HOLDINGS, INC.

Sernova Biotherapeutics Inc. has been told by Dr. Steven Sangha that he has entered into a voting and support agreement with Seraxis Holdings, Inc. in connection with Seraxis's proposal to acquire all of the securities of Sernova Biotherapeutics pursuant to an arrangement agreement dated Sept. 7, 2026, between Seraxis and Sernova.

Pursuant to the arrangement agreement, holders of Sernova securities will receive Seraxis securities based on the applicable exchange ratio, with each outstanding Sernova common share being exchanged for 0.0112746082 of a Seraxis common share, and each Sernova share issued upon conversion of Sernova subscription receipts offered pursuant to the upcoming private placement financing being exchanged for 0.0132400349 of a Seraxis common share, subject to adjustment in certain circumstances.

Pursuant to the voting agreement, Dr. Sangha has agreed, among other things, to (i) vote all of his Sernova securities and any Sernova securities thereafter acquired (that are entitled to vote) in favour of the approval of the proposed transaction (or if applicable, the "alternative transaction" as defined therein), and (ii) restrict any disposition of his Sernova securities.

Dr. Sangha beneficially owns and controls (i) 39,703,667 common shares of Sernova, (ii) 53,575,759 Sernova share purchase warrants, (iii) $2.9-million principal amount of Sernova convertible debentures, convertible into 17,909,092 Sernova shares, and (iv) 2,540,237 options to acquire Sernova shares, representing approximately 10.5 per cent of the outstanding Sernova shares on a non-diluted basis, and approximately 30.0 per cent on a partially diluted basis assuming exercise of such warrants and vested options. Each of the above convertible debentures have 9.99-per-cent or 19.99-per-cent "blocker" limits on conversion, so Dr. Sangha is currently restricted from converting the principal amount of such debentures into Sernova shares.

Dr. Sangha holds the Sernova securities for investment purposes and to support the proposed transaction. If the voting agreement is terminated, Dr. Sangha may acquire additional securities of Sernova or sell Sernova securities in the future depending on market conditions, reformulation of plans and/or other relevant factors.

Sernova is located at PO Box 29592, RPO Central Parkway, Mississauga, Ont., L5A 4H2. A copy of Dr. Sangha's early warning report will appear on Sernova's profile on SEDAR+ and may also be obtained by calling David Burke at 917-751-5713.

© 2026 Canjex Publishing Ltd. All rights reserved.